Dr. Daniel Von Hoff named honoree of Scottsdale Healthcare Foundation Honor Ball

December 09, 2009

SCOTTSDALE, Ariz. (Dec. 9, 2009) - Scottsdale Healthcare Foundation announced today that Daniel Von Hoff, MD will be Honoree at its 34th annual Honor Ball. Dr. Von Hoff, an oncologist and chief scientific officer at Scottsdale Healthcare's Virginia G. Piper Cancer Center, is known worldwide for his groundbreaking cancer research.

One of Arizona's most elegant and exciting black tie events, The Honor Ball will be held Saturday evening, Feb. 6, 2010 in The Phoenician Resort Grand Ballroom. Proceeds from the event will benefit cancer research and treatment at Scottsdale Healthcare's Virginia G. Piper Cancer Center.

Dr. Von Hoff is internationally known for his research in pancreatic, basal cell and other cancers. His findings have been published in the prestigious in the New England Journal of Medicine, most recently for a breakthrough in treating advanced basal cell carcinoma led by Dr. Von Hoff and his team in the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

An advocate of targeted therapy known as precision oncology, Dr. Von Hoff is co-leader of the Stand Up to Cancer (SU2C) Pancreatic Cancer Dream Team, created with an $18 million grant from the Entertainment Industry Foundation to investigate new approaches for treating pancreatic cancer, the fourth leading cause of cancer death in the United States.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare offers cancer diagnosis, treatment, research, prevention and support services in its facilities at the Scottsdale Healthcare Shea Medical Center, attracting patients from across Arizona and the U.S.

"I'm humbled to be selected as the Honor Ball Honoree this year, but glad that the Virginia G. Piper Cancer Center has been selected as beneficiary. The team works so hard to bring comfort to our patients, and we know we have a very special place here," said Dr. Von Hoff. "We promise you that we will do everything in our power, with your help, to make a dent against this disease."

In his dual roles at Scottsdale Healthcare and as physician-in-chief at Translational Genomics Research Institute (TGen), Dr. Von Hoff leads a team of world-class cancer researchers in the TGen Clinical Research Services at Scottsdale Healthcare (TCRS) clinic in the Virginia G. Piper Cancer Center.

Several studies conducted at Scottsdale Healthcare have yielded promising results to advance the battle against cancer. Skin, lung and pancreatic cancer clinical trials conducted at Scottsdale Healthcare have been the subject of scientific papers and presentations at recent international cancer conferences.

New drugs and therapies studied here are the first step from the research lab to cancer patients. Successful results may lead to eventual approval from the U.S. Food and Drug Administration to become standard treatment. Clinical trials in the Virginia G. Piper Cancer Center are administered by the Scottsdale Clinical Research Institute.

TCRS is a partnership of the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare. The partnership allows molecular and genomic discoveries made by TGen and others around the world to reach patients in the Virginia G. Piper Cancer Center at Scottsdale Healthcare as quickly as possible through clinical trials with agents directed at specific targets in patients' tumors.

"Cancer patients in our community have access to this ground-breaking, world-class research right in their own backyard," said Mark Slater, PhD, vice president of research at Scottsdale Healthcare. "Our goal is reducing the time it takes to get new treatment discoveries from the research lab to the patient, and we are pleased that proceeds from The Honor Ball will support this important work."

The Honor Ball has raised more than $8 million through individual and corporate donations to benefit Scottsdale Healthcare.

"Dr. Von Hoff is a world-renowned cancer researcher and the Virginia G. Piper Cancer Center at Scottsdale Healthcare has gained an outstanding reputation as 'the place to be treated' for cancer patients," said 2010 Honor Ball Chair Sandy Trznadel.

"Healing and hope come together here" she added. "Staff at the cancer center like to say, 'we take your fight with cancer personally.' With the support of the Honor Ball, the Virginia G. Piper Cancer Center at Scottsdale Healthcare will continue to grow and achieve great milestones."
-end-
Scottsdale Healthcare (ww.shc.org) is the not-for-profit parent organization of Scottsdale Healthcare Thompson Peak Hospital, Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center, Virginia G. Piper Cancer Center, Scottsdale Healthcare Clinical Research Institute, Scottsdale Healthcare Home Health Services, Scottsdale Healthcare Community Health Services and NOAH Clinics. Scottsdale Healthcare Foundation is the philanthropic arm of Scottsdale Healthcare.

About Dr. Daniel Von Hoff

In addition to his positions at Scottsdale Healthcare and TGen, Dr. Von Hoff is chief scientific officer for US Oncology, and clinical professor of medicine at the University of Arizona.

His major interest is in the development of new anticancer agents. Dr. Von Hoff's work focuses on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.

Dr. Von Hoff is serving a six-year term on the National Cancer Advisory Board and has served on the FDA's Oncology Advisory Committee.

He is a past president of the American Association for Cancer Research, the largest cancer research organization in the world dedicated to the prevention and cure of cancer. He was on the AACR and the American Society of Clinical Oncology's Board of Directors, and is a fellow of the American College of Physicians.

Scottsdale Healthcare

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.